Roaccutane - UK-Muscle Body Building Community

**Great White** · 18-02-2004, 05:18 PM

Hey gang

Got some of this for my spots on my back.

Need to get them under control for the summer.

This is a VERY strong drug and I understand there can be some sever side effects.

I never got them from the docs - Mate gave them to me, he has a few boxes left once he ran a course of em

I have started, but im a bit weary to carry on as there are some very very nasty sides that may be accociated with it.

Anyone used this stuff?

Please give me advise if you know any on this stuff

Thanks

Paul

**hackskii** · 18-02-2004, 05:47 PM

I gont think taking gear with this is good as it affects the liver function, see below:

WARNINGS
You are reminded that Roaccutane is a scheduled medicine and not a cosmetic agent and that it is a criminal act to transfer it to any person not in possession of a valid prescription.
Hepatotoxicity: Liver function should be checked before and one month after the start of treatment, and subsequently at three-monthly intervals.
Several cases of clinical hepatitis have been noted which are considered to be possibly or probably related to Roaccutane therapy. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials, some of which normalised with dosage reduction or continued administration of the drug. If normalisation does not readily occur or if hepatitis is suspected during treatment with Roaccutane, the drug should be discontinued and the aetiology further investigated.
Psychiatric Disorders: Roaccutane may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts and suicide. Discontinuation of Roaccutane therapy may be insufficient; further evaluation may be necessary. No mechanism of action has been established for these events.
Pseudotumor Cerebri: Roaccutane use has been associated with a number of eases of pseudotumor cerebri (benign intracranial hypertension). Early signs and symptoms of pseudotumor cerebri include papilloedema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilloedema and, if present, they should be told to discontinue Roaccutane immediately and be referred to a neurologist for further diagnosis and care.
Corneal Opacities: Corneal opacities have occurred in patients receiving Roaccutane for acne and more frequently when higher drug dosages were used in patients with disorders of keratinization. All Roaccutane patients experiencing visual difficulties should discontinue the drug and have an ophthalmological examination. The corneal opacities that have been observed in patients treated with Roaccutane have either completely resolved or were resolving at follow-up 6 to 7 weeks after discontinuation of the drug.
Lipids: Blood lipid determinations should be performed before Roaccutane is given and then at intervals until the lipid response to Roaccutane is established, which usually occurs within 4 weeks. Approximately, 25% of patients receiving Roaccutane experience an elevation in plasma triglycerides. Approximately 15% developed a decrease in high density lipoproteins and about 7% showed an increase in cholesterol levels. These effects on triglycerides, HDL and cholesterol were reversible upon cessation of Roaccutane therapy.
Patients with increased tendency to develop hypertriglyceridemia include those with diabetes mellitus, obesity, increased alcohol intake and familial history.
Diabetes Mellitus: In diabetic patients, frequent determination of blood glucose levels is recommended. New cases of diabetes mellitus have been diagnosed during Roaccutane therapy.
Decreased Night Vision: A number of cases of decreased night vision have occurred during Roaccutane therapy. Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicles at night. Visual problems should be carefully monitored.
Hyperostosis: In clinical trials of disorders of keratinization with a mean dose of 2,24 mg/kg/day a high prevalence of skeletal hyperostosis was noted. Two children showed X-ray findings suggestive of premature closure of the epiphysis. Additionally, skeletal hyperostosis was noted in 6 of 8 patients in a prospective study of disorders of keratinization. Skeletal hyperostosis has also been observed by X-rays in prospective studies of nodular acne patients treated with a single course of therapy at recommended doses.
Inflammatory Bowel Disease: Roaccutane has been temporarily associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. Patients experiencing abdominal pain, rectal bleeding or severe diarrhoea should discontinue Roaccutane immediately.
Females of childbearing potential should be instructed that they must not be pregnant when Roaccutane therapy is initiated, and that they should use effective contraception while taking Roaccutane without any interruptions for 1 month prior to therapy, the duration of therapy and for 1 month after discontinuation of therapy. It is recommended that two reliable forms of contraception be used simultaneously unless abstinence is the chosen method. They should also sign a consent form prior to beginning Roaccutane therapy (see boxed CONTRA-INDICATIONS).
Because of the relationship of Roaccutane to Vitamin A, patients should be advised against taking vitamin supplements containing Vitamin A to avoid toxic effects.
Patients should be informed that transient exacerbation of acne has been seen, generally during the initial period of therapy. .
Patients should be informed that they may experience decreased tolerance to contact lenses during and after therapy.
It is recommended that patients do not donate blood during and for 1 month after stopping therapy with Roaccutane.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS
Every patient should be warned about the possible occurrence of side-effects.
The initial diagnosis, and prescription of Roaccutane should ideally be performed by a dermatologist.
Most of the side-effects of Roaccutane are dose-related.
The side-effects are listed below in order of frequency of occurrence within each organ-system:
Central nervous system: (See Warnings)
Cases of pseudotumor cerebri (see WARNINGS), visual disturbances, hearing deficiency in certain frequencies, as well as headache, nausea, malaise and drowsiness have been observed.
Psychiatric Adverseeffects: (See Warnings)
Behavioural disorders or seizures have been observed.
In the post-marketing period, a number of patients treated with Roaccutane have reported depression psychosis and. rarely, suicidal ideation, suicide attempts and suicide. Of the patients reporting depression, some reported that the depression subsided with the discontinuation of therapy an recurred with reinstitution of therapy (see WARNINGS).
Mucous membrane and skin manifestations:
The most frequently observed symptoms are those associated with hypervitaminosis A, i.e. dryness of the mucosae, which on the lips can be relieved by application of a fatty ointment; dryness of the nasal mucosae can lead to epistaxis; dryness of the pharyngeal mucosa to ho****ness.
Dermatitis facialis, exanthema, pyogenic granuloma, paronychia, nail dystrophy, pruritis, sweating and increased formation of granulation tissue in the acne eruptions may occur.
Patients may experience photosensitivity reactions.
Keratitis in association with Roaccutane treatment has been reported less frequently, and is possibly related to the dry eye syndrome. Therefore patients, particularly those with dry eye syndrome, should be monitored for the development of keratitis, even after the discontinuation of Roaccutane treatment.
Effects on lipid metabolism: (See Warnings)
Increases in serum triglyceride plus cholesterol levels as well as decrease of HDL have also been observed, particularly at high dosages and in predisposed patients (with a family history of lipid metabolism disorders, diabetes, obesity or alcoholism). These changes are dose-related, and values return to normal on reduction of the dosage or withdrawal of the drug.
Liver effects: (See Warnings)
Reversible increases in transaminases have been observed in 15% of patients as well as some cases of hepatitis possibly related to Roaccutane have been observed, and it may be necessary to reduce the dosage or discontinue treatment. Isotretinoin-treated patients with high serum triglycerides (> 800 mg %) are at risk to develop pancreatitis.
Effects on lipids and triglycerides:(See Warnings)
Ocular manifestations:(See Warnings)
Dryness of the eyes can cause conjunctivitis and reversible corneal opacities. Conjunctivitis may be improved by a mild eye ointment.
Intolerance to contact lenses may force the patient to wear glasses during treatment.
Isolated cases of decreased night vision and lenticular cataract have been reported.
Patients experiencing visual disturbances should be referred for an expert opthalmological examination and withdrawal of Roaccutane should be considered.
Musculoskeletal effects:
The following bone changes have occurred in children and adults treated with high doses of Roaccutane for indications other than acne: premature epiphyseal closure and skeletal hyperostosis.
Skeletal hyperostosis has been observed in cystic acne patients treated with a single course of Roaccutane. Due to the possible occurrence of these bone changes, a careful evaluation of the risk/benefit-ratio should be carried out in every patient and Roaccutane administration should be restricted to severe cases.
Muscle and joint pain have been observed.
Haematological effects:
Isolated cases of anaemia, neutropenia and thrombocytopenia.
Laboratory abnormalities:
Hyperuricaemia, hematuria/proteinuria
Miscellaneous:
Cases of persistent hair thinning have been reported. Reversible alopecia has been observed. Hirsutism and hyperpigmentation (facial) have been reported. Lymphadenopathy has also been reported.
Allergic vasculitis, including Wegener's granulomatosis. Acne fulminans.
Inflammatory bowel disease e.g. colitis, ileitis, haemorrhage.
Local or systemic infections with Gram positive micro-organisms (Staphylococcus aureus).
Drug interactions:
Concurrent therapy with Roaccutane and vitamin A must be avoided, as symptoms of hypervitaminosis A may be intensified.
Cases of benign intracranial hypertension have been reported after Roaccutane and the use of tetracyclines. Supplementary treatment with tetracyclines is therefore contra- indicated.
No interactions between Roaccutane and other drugs (e.g. oral contraceptives) have been observed to date.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
Although the acute toxicity of Roaccutane is low, signs of hypervitaminosis A could appear in cases of accidental overdose. Evacuation of the stomach may be indicated in the first few hours after overdosage. Further treatment is supportive and symptomatic.

Panthro · 18-02-2004, 06:47 PM

my dad is a dermatologist and under NO circumstances should it be self administered, ESPECIALLY when on gear! Absolutely no way! When a Dr puts you on it, you have regular liver checks etc, it is a serious drug.

Go see your doc, and he will prescribe you something much milder, like oxytetracycline or eyrth...something or other.

Drop it asap mate

**Great White** · 19-02-2004, 11:52 AM

Cool

I`ll stop it today

Only taken 5 or 6 tablets so no damage should have been done yet

Thanks

Paul

18-02-2004, 05:18 PM	#1 (permalink)
Great White Sexy Moderator Join Date: Apr 2003 Location: United Kingdom Posts: 9,249	Roaccutane Hey gang Got some of this for my spots on my back. Need to get them under control for the summer. This is a VERY strong drug and I understand there can be some sever side effects. I never got them from the docs - Mate gave them to me, he has a few boxes left once he ran a course of em I have started, but im a bit weary to carry on as there are some very very nasty sides that may be accociated with it. Anyone used this stuff? Please give me advise if you know any on this stuff Thanks Paul __________________ Welcome to Uk-Muscle.co.uk "I was born perfect, and just like the great white shark, have never had to evolve!" To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts. - Hardcore Bodybuilding & Powerlifting Community! To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts. - Bodybuilding & Sports Video Sharing Community!

18-02-2004, 05:47 PM	#2 (permalink)
hackskii UK-Muscle Moderator Join Date: Jul 2003 Location: Sunny Southern California U.S.A. Posts: 23,135	I gont think taking gear with this is good as it affects the liver function, see below: WARNINGS You are reminded that Roaccutane is a scheduled medicine and not a cosmetic agent and that it is a criminal act to transfer it to any person not in possession of a valid prescription. Hepatotoxicity: Liver function should be checked before and one month after the start of treatment, and subsequently at three-monthly intervals. Several cases of clinical hepatitis have been noted which are considered to be possibly or probably related to Roaccutane therapy. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials, some of which normalised with dosage reduction or continued administration of the drug. If normalisation does not readily occur or if hepatitis is suspected during treatment with Roaccutane, the drug should be discontinued and the aetiology further investigated. Psychiatric Disorders: Roaccutane may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts and suicide. Discontinuation of Roaccutane therapy may be insufficient; further evaluation may be necessary. No mechanism of action has been established for these events. Pseudotumor Cerebri: Roaccutane use has been associated with a number of eases of pseudotumor cerebri (benign intracranial hypertension). Early signs and symptoms of pseudotumor cerebri include papilloedema, headache, nausea and vomiting, and visual disturbances. Patients with these symptoms should be screened for papilloedema and, if present, they should be told to discontinue Roaccutane immediately and be referred to a neurologist for further diagnosis and care. Corneal Opacities: Corneal opacities have occurred in patients receiving Roaccutane for acne and more frequently when higher drug dosages were used in patients with disorders of keratinization. All Roaccutane patients experiencing visual difficulties should discontinue the drug and have an ophthalmological examination. The corneal opacities that have been observed in patients treated with Roaccutane have either completely resolved or were resolving at follow-up 6 to 7 weeks after discontinuation of the drug. Lipids: Blood lipid determinations should be performed before Roaccutane is given and then at intervals until the lipid response to Roaccutane is established, which usually occurs within 4 weeks. Approximately, 25% of patients receiving Roaccutane experience an elevation in plasma triglycerides. Approximately 15% developed a decrease in high density lipoproteins and about 7% showed an increase in cholesterol levels. These effects on triglycerides, HDL and cholesterol were reversible upon cessation of Roaccutane therapy. Patients with increased tendency to develop hypertriglyceridemia include those with diabetes mellitus, obesity, increased alcohol intake and familial history. Diabetes Mellitus: In diabetic patients, frequent determination of blood glucose levels is recommended. New cases of diabetes mellitus have been diagnosed during Roaccutane therapy. Decreased Night Vision: A number of cases of decreased night vision have occurred during Roaccutane therapy. Because the onset in some patients was sudden, patients should be advised of this potential problem and warned to be cautious when driving or operating any vehicles at night. Visual problems should be carefully monitored. Hyperostosis: In clinical trials of disorders of keratinization with a mean dose of 2,24 mg/kg/day a high prevalence of skeletal hyperostosis was noted. Two children showed X-ray findings suggestive of premature closure of the epiphysis. Additionally, skeletal hyperostosis was noted in 6 of 8 patients in a prospective study of disorders of keratinization. Skeletal hyperostosis has also been observed by X-rays in prospective studies of nodular acne patients treated with a single course of therapy at recommended doses. Inflammatory Bowel Disease: Roaccutane has been temporarily associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. Patients experiencing abdominal pain, rectal bleeding or severe diarrhoea should discontinue Roaccutane immediately. Females of childbearing potential should be instructed that they must not be pregnant when Roaccutane therapy is initiated, and that they should use effective contraception while taking Roaccutane without any interruptions for 1 month prior to therapy, the duration of therapy and for 1 month after discontinuation of therapy. It is recommended that two reliable forms of contraception be used simultaneously unless abstinence is the chosen method. They should also sign a consent form prior to beginning Roaccutane therapy (see boxed CONTRA-INDICATIONS). Because of the relationship of Roaccutane to Vitamin A, patients should be advised against taking vitamin supplements containing Vitamin A to avoid toxic effects. Patients should be informed that transient exacerbation of acne has been seen, generally during the initial period of therapy. . Patients should be informed that they may experience decreased tolerance to contact lenses during and after therapy. It is recommended that patients do not donate blood during and for 1 month after stopping therapy with Roaccutane. SIDE-EFFECTS AND SPECIAL PRECAUTIONS Every patient should be warned about the possible occurrence of side-effects. The initial diagnosis, and prescription of Roaccutane should ideally be performed by a dermatologist. Most of the side-effects of Roaccutane are dose-related. The side-effects are listed below in order of frequency of occurrence within each organ-system: Central nervous system: (See Warnings) Cases of pseudotumor cerebri (see WARNINGS), visual disturbances, hearing deficiency in certain frequencies, as well as headache, nausea, malaise and drowsiness have been observed. Psychiatric Adverseeffects: (See Warnings) Behavioural disorders or seizures have been observed. In the post-marketing period, a number of patients treated with Roaccutane have reported depression psychosis and. rarely, suicidal ideation, suicide attempts and suicide. Of the patients reporting depression, some reported that the depression subsided with the discontinuation of therapy an recurred with reinstitution of therapy (see WARNINGS). Mucous membrane and skin manifestations: The most frequently observed symptoms are those associated with hypervitaminosis A, i.e. dryness of the mucosae, which on the lips can be relieved by application of a fatty ointment; dryness of the nasal mucosae can lead to epistaxis; dryness of the pharyngeal mucosa to ho**ness. Dermatitis facialis, exanthema, pyogenic granuloma, paronychia, nail dystrophy, pruritis, sweating and increased formation of granulation tissue in the acne eruptions may occur. Patients may experience photosensitivity reactions. Keratitis in association with Roaccutane treatment has been reported less frequently, and is possibly related to the dry eye syndrome. Therefore patients, particularly those with dry eye syndrome, should be monitored for the development of keratitis, even after the discontinuation of Roaccutane treatment. Effects on lipid metabolism: (See Warnings) Increases in serum triglyceride plus cholesterol levels as well as decrease of HDL have also been observed, particularly at high dosages and in predisposed patients (with a family history of lipid metabolism disorders, diabetes, obesity or alcoholism). These changes are dose-related, and values return to normal on reduction of the dosage or withdrawal of the drug. Liver effects: (See Warnings) Reversible increases in transaminases have been observed in 15% of patients as well as some cases of hepatitis possibly related to Roaccutane have been observed, and it may be necessary to reduce the dosage or discontinue treatment. Isotretinoin-treated patients with high serum triglycerides (> 800 mg %) are at risk to develop pancreatitis. Effects on lipids and triglycerides:(See Warnings) Ocular manifestations:(See Warnings) Dryness of the eyes can cause conjunctivitis and reversible corneal opacities. Conjunctivitis may be improved by a mild eye ointment. Intolerance to contact lenses may force the patient to wear glasses during treatment. Isolated cases of decreased night vision and lenticular cataract have been reported. Patients experiencing visual disturbances should be referred for an expert opthalmological examination and withdrawal of Roaccutane should be considered. Musculoskeletal effects: The following bone changes have occurred in children and adults treated with high doses of Roaccutane for indications other than acne: premature epiphyseal closure and skeletal hyperostosis. Skeletal hyperostosis has been observed in cystic acne patients treated with a single course of Roaccutane. Due to the possible occurrence of these bone changes, a careful evaluation of the risk/benefit-ratio should be carried out in every patient and Roaccutane administration should be restricted to severe cases. Muscle and joint pain have been observed. Haematological effects: Isolated cases of anaemia, neutropenia and thrombocytopenia. Laboratory abnormalities: Hyperuricaemia, hematuria/proteinuria Miscellaneous: Cases of persistent hair thinning have been reported. Reversible alopecia has been observed. Hirsutism and hyperpigmentation (facial) have been reported. Lymphadenopathy has also been reported. Allergic vasculitis, including Wegener's granulomatosis. Acne fulminans. Inflammatory bowel disease e.g. colitis, ileitis, haemorrhage. Local or systemic infections with Gram positive micro-organisms (Staphylococcus aureus). Drug interactions: Concurrent therapy with Roaccutane and vitamin A must be avoided, as symptoms of hypervitaminosis A may be intensified. Cases of benign intracranial hypertension have been reported after Roaccutane and the use of tetracyclines. Supplementary treatment with tetracyclines is therefore contra- indicated. No interactions between Roaccutane and other drugs (e.g. oral contraceptives) have been observed to date. KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT Although the acute toxicity of Roaccutane is low, signs of hypervitaminosis A could appear in cases of accidental overdose. Evacuation of the stomach may be indicated in the first few hours after overdosage. Further treatment is supportive and symptomatic. __________________ "Life is not measured by the number of breaths we take, but by the moments that take our breath away." - George Carlin Scott** To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts.

18-02-2004, 06:47 PM	#3 (permalink)
Panthro Getting HUGE! Join Date: Jan 2004 Posts: 1,508	my dad is a dermatologist and under NO circumstances should it be self administered, ESPECIALLY when on gear! Absolutely no way! When a Dr puts you on it, you have regular liver checks etc, it is a serious drug. Go see your doc, and he will prescribe you something much milder, like oxytetracycline or eyrth...something or other. Drop it asap mate __________________ "looking at picutres of half naked men dont get you strong. Lets get down to business and go to the gym" - Svend Karlson. 'Viking Power'

19-02-2004, 11:52 AM	#4 (permalink)
Great White Sexy Moderator Join Date: Apr 2003 Location: United Kingdom Posts: 9,249	Cool I`ll stop it today Only taken 5 or 6 tablets so no damage should have been done yet Thanks Paul __________________ Welcome to Uk-Muscle.co.uk "I was born perfect, and just like the great white shark, have never had to evolve!" To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts. - Hardcore Bodybuilding & Powerlifting Community! To view links or images in signatures your post count must be 0 or greater. You currently have 0 posts. - Bodybuilding & Sports Video Sharing Community!

Thread Tools
Show Printable Version Email this Page
Rate This Thread
Rate This Thread: